208 related articles for article (PubMed ID: 10076915)
1. Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists.
Sever PS
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S3-10; discussion S33-4. PubMed ID: 10076915
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
Malmqvist K; Kahan T; Dahl M
Am J Hypertens; 2000 May; 13(5 Pt 1):504-11. PubMed ID: 10826401
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial.
Association of Black Cardiologists (ABC) Candesartan Study Group
Heart Dis; 2000; 2(6):392-9. PubMed ID: 11728289
[TBL] [Abstract][Full Text] [Related]
4. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
Sever PS
J Hypertens Suppl; 1997 Dec; 15(6):S9-12. PubMed ID: 9493121
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.
McInnes GT; O'Kane KP; Istad H; Keinänen-Kiukaanniemi S; Van Mierlo HF
J Hum Hypertens; 2000 Apr; 14(4):263-9. PubMed ID: 10805052
[TBL] [Abstract][Full Text] [Related]
6. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators.
Oparil S; Levine JH; Zuschke CA; Gradman AH; Ripley E; Jones DW; Hardison JD; Cushing DJ; Prasad R; Michelson EL
Am J Cardiol; 1999 Aug; 84(3):289-93. PubMed ID: 10496437
[TBL] [Abstract][Full Text] [Related]
7. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
Sever PS
Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
[TBL] [Abstract][Full Text] [Related]
8. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
Sever P
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators.
Lacourcière Y; Asmar R
Am J Hypertens; 1999 Dec; 12(12 Pt 1-2):1181-7. PubMed ID: 10619580
[TBL] [Abstract][Full Text] [Related]
10. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
Melian EB; Jarvis B
Drugs; 2002; 62(5):787-816. PubMed ID: 11929332
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators.
MacGregor GA; Viskoper JR; Antonios TF; He FJ
Hypertension; 2000 Sep; 36(3):454-60. PubMed ID: 10988281
[TBL] [Abstract][Full Text] [Related]
12. Candesartan cilexetil: an angiotensin II-receptor blocker.
See S; Stirling AL
Am J Health Syst Pharm; 2000 Apr; 57(8):739-46. PubMed ID: 10786259
[TBL] [Abstract][Full Text] [Related]
13. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
Andersson OK; Neldam S
Blood Press; 1998 Jan; 7(1):53-9. PubMed ID: 9551878
[TBL] [Abstract][Full Text] [Related]
14. Candesartan cilexetil. A review of its use in essential hypertension.
McClellan KJ; Goa KL
Drugs; 1998 Nov; 56(5):847-69. PubMed ID: 9829158
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
Ogihara T; Arakawa K
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
[TBL] [Abstract][Full Text] [Related]
16. Candesartan cilexetil: an angiotensin II receptor blocker.
Stoukides CA; McVoy HJ; Kaul AF
Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
[TBL] [Abstract][Full Text] [Related]
17. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
Weber MA
J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
[TBL] [Abstract][Full Text] [Related]
18. Candesartan cilexetil: an update of its use in essential hypertension.
Easthope SE; Jarvis B
Drugs; 2002; 62(8):1253-87. PubMed ID: 12010090
[TBL] [Abstract][Full Text] [Related]
19. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Baumgart P; Reismann J; Pohlmeyer H; Düsing R
Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]